Forskning
Udskriv Udskriv
Switch language
Hvidovre Hospital - en del af Københavns Universitetshospital
Udgivet

Improved Survival Among Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Treated With Remdesivir and Dexamethasone. A Nationwide Population-Based Cohort Study

Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

Harvard

Benfield, T, Bodilsen, J, Brieghel, C, Harboe, ZB, Helleberg, M, Holm, C, Israelsen, SB, Jensen, J, Jensen, TØ, Johansen, IS, Johnsen, S, Madsen, BL, Lundgren, J, Meyer, CN, Mohey, R, Pedersen, LM, Nielsen, H, Nielsen, SL, Obel, N, Omland, LH, Podlekareva, D, Poulsen, BK, Ravn, P, Sandholdt, H, Starling, J, Storgaard, M, Søborg, C, Søgaard, OS, Tranborg, T, Wiese, L & Christensen, HR 2021, 'Improved Survival Among Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Treated With Remdesivir and Dexamethasone. A Nationwide Population-Based Cohort Study', Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, bind 73, nr. 11, s. 2031-2036. https://doi.org/10.1093/cid/ciab536

APA

CBE

Benfield T, Bodilsen J, Brieghel C, Harboe ZB, Helleberg M, Holm C, Israelsen SB, Jensen J, Jensen TØ, Johansen IS, Johnsen S, Madsen BL, Lundgren J, Meyer CN, Mohey R, Pedersen LM, Nielsen H, Nielsen SL, Obel N, Omland LH, Podlekareva D, Poulsen BK, Ravn P, Sandholdt H, Starling J, Storgaard M, Søborg C, Søgaard OS, Tranborg T, Wiese L, Christensen HR. 2021. Improved Survival Among Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Treated With Remdesivir and Dexamethasone. A Nationwide Population-Based Cohort Study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 73(11):2031-2036. https://doi.org/10.1093/cid/ciab536

MLA

Vancouver

Author

Benfield, Thomas ; Bodilsen, Jacob ; Brieghel, Christian ; Harboe, Zitta Barrella ; Helleberg, Marie ; Holm, Claire ; Israelsen, Simone Bastrup ; Jensen, Janne ; Jensen, Tomas Østergaard ; Johansen, Isik Somuncu ; Johnsen, Stine ; Madsen, Birgitte Lindegaard ; Lundgren, Jens ; Meyer, Christian Niels ; Mohey, Rajesh ; Pedersen, Lars Møller ; Nielsen, Henrik ; Nielsen, Stig Lønberg ; Obel, Niels ; Omland, Lars Haukali ; Podlekareva, Daria ; Poulsen, Birgitte Klindt ; Ravn, Pernille ; Sandholdt, Haakon ; Starling, Jonathan ; Storgaard, Merete ; Søborg, Christian ; Søgaard, Ole Schmeltz ; Tranborg, Torben ; Wiese, Lothar ; Christensen, Hanne Rolighed. / Improved Survival Among Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Treated With Remdesivir and Dexamethasone. A Nationwide Population-Based Cohort Study. I: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2021 ; Bind 73, Nr. 11. s. 2031-2036.

Bibtex

@article{2274766b696c4f5190614353879b8ba2,
title = "Improved Survival Among Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Treated With Remdesivir and Dexamethasone. A Nationwide Population-Based Cohort Study",
abstract = "BACKGROUND: There are limited data on outcomes of moderate to severe coronavirus disease 2019 (COVID-19) among patients treated with remdesivir and dexamethasone in a real-world setting. We sought to compare the effectiveness of standard of care (SOC) alone versus SOC plus remdesivir and dexamethasone.METHODS: Two population-based nationwide cohorts of individuals hospitalized with COVID-19 during February through December 2020 were studied. Death within 30 days and need of mechanical ventilation (MV) were compared by inverse probability of treatment weighted (ITPW) logistic regression analysis and shown as odds ratio (OR) with 95% confidence interval (CI).RESULTS: The 30-days mortality rate of 1694 individuals treated with remdesivir and dexamethasone in addition to SOC was 12.6% compared to 19.7% for 1053 individuals receiving SOC alone. This corresponded to a weighted OR of 30-day mortality of 0.47 (95% CI: .38-.57) for patients treated with remdesivir and dexamethasone compared to patients receiving SOC alone. Similarly, progression to MV was reduced (OR 0.36; 95% CI: .29-.46).CONCLUSIONS: Treatment of moderate to severe COVID-19 during June through December that included remdesivir and dexamethasone was associated with reduced 30-day mortality and need of MV compared to treatment in February through May.",
keywords = "Adenosine Monophosphate/analogs & derivatives, Alanine/analogs & derivatives, Antiviral Agents/therapeutic use, COVID-19/drug therapy, Cohort Studies, Dexamethasone/therapeutic use, Humans, Retrospective Studies, SARS-CoV-2",
author = "Thomas Benfield and Jacob Bodilsen and Christian Brieghel and Harboe, {Zitta Barrella} and Marie Helleberg and Claire Holm and Israelsen, {Simone Bastrup} and Janne Jensen and Jensen, {Tomas {\O}stergaard} and Johansen, {Isik Somuncu} and Stine Johnsen and Madsen, {Birgitte Lindegaard} and Jens Lundgren and Meyer, {Christian Niels} and Rajesh Mohey and Pedersen, {Lars M{\o}ller} and Henrik Nielsen and Nielsen, {Stig L{\o}nberg} and Niels Obel and Omland, {Lars Haukali} and Daria Podlekareva and Poulsen, {Birgitte Klindt} and Pernille Ravn and Haakon Sandholdt and Jonathan Starling and Merete Storgaard and Christian S{\o}borg and S{\o}gaard, {Ole Schmeltz} and Torben Tranborg and Lothar Wiese and Christensen, {Hanne Rolighed}",
note = "{\textcopyright} The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.",
year = "2021",
month = dec,
day = "6",
doi = "10.1093/cid/ciab536",
language = "English",
volume = "73",
pages = "2031--2036",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "University of Chicago Press",
number = "11",

}

RIS

TY - JOUR

T1 - Improved Survival Among Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Treated With Remdesivir and Dexamethasone. A Nationwide Population-Based Cohort Study

AU - Benfield, Thomas

AU - Bodilsen, Jacob

AU - Brieghel, Christian

AU - Harboe, Zitta Barrella

AU - Helleberg, Marie

AU - Holm, Claire

AU - Israelsen, Simone Bastrup

AU - Jensen, Janne

AU - Jensen, Tomas Østergaard

AU - Johansen, Isik Somuncu

AU - Johnsen, Stine

AU - Madsen, Birgitte Lindegaard

AU - Lundgren, Jens

AU - Meyer, Christian Niels

AU - Mohey, Rajesh

AU - Pedersen, Lars Møller

AU - Nielsen, Henrik

AU - Nielsen, Stig Lønberg

AU - Obel, Niels

AU - Omland, Lars Haukali

AU - Podlekareva, Daria

AU - Poulsen, Birgitte Klindt

AU - Ravn, Pernille

AU - Sandholdt, Haakon

AU - Starling, Jonathan

AU - Storgaard, Merete

AU - Søborg, Christian

AU - Søgaard, Ole Schmeltz

AU - Tranborg, Torben

AU - Wiese, Lothar

AU - Christensen, Hanne Rolighed

N1 - © The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

PY - 2021/12/6

Y1 - 2021/12/6

N2 - BACKGROUND: There are limited data on outcomes of moderate to severe coronavirus disease 2019 (COVID-19) among patients treated with remdesivir and dexamethasone in a real-world setting. We sought to compare the effectiveness of standard of care (SOC) alone versus SOC plus remdesivir and dexamethasone.METHODS: Two population-based nationwide cohorts of individuals hospitalized with COVID-19 during February through December 2020 were studied. Death within 30 days and need of mechanical ventilation (MV) were compared by inverse probability of treatment weighted (ITPW) logistic regression analysis and shown as odds ratio (OR) with 95% confidence interval (CI).RESULTS: The 30-days mortality rate of 1694 individuals treated with remdesivir and dexamethasone in addition to SOC was 12.6% compared to 19.7% for 1053 individuals receiving SOC alone. This corresponded to a weighted OR of 30-day mortality of 0.47 (95% CI: .38-.57) for patients treated with remdesivir and dexamethasone compared to patients receiving SOC alone. Similarly, progression to MV was reduced (OR 0.36; 95% CI: .29-.46).CONCLUSIONS: Treatment of moderate to severe COVID-19 during June through December that included remdesivir and dexamethasone was associated with reduced 30-day mortality and need of MV compared to treatment in February through May.

AB - BACKGROUND: There are limited data on outcomes of moderate to severe coronavirus disease 2019 (COVID-19) among patients treated with remdesivir and dexamethasone in a real-world setting. We sought to compare the effectiveness of standard of care (SOC) alone versus SOC plus remdesivir and dexamethasone.METHODS: Two population-based nationwide cohorts of individuals hospitalized with COVID-19 during February through December 2020 were studied. Death within 30 days and need of mechanical ventilation (MV) were compared by inverse probability of treatment weighted (ITPW) logistic regression analysis and shown as odds ratio (OR) with 95% confidence interval (CI).RESULTS: The 30-days mortality rate of 1694 individuals treated with remdesivir and dexamethasone in addition to SOC was 12.6% compared to 19.7% for 1053 individuals receiving SOC alone. This corresponded to a weighted OR of 30-day mortality of 0.47 (95% CI: .38-.57) for patients treated with remdesivir and dexamethasone compared to patients receiving SOC alone. Similarly, progression to MV was reduced (OR 0.36; 95% CI: .29-.46).CONCLUSIONS: Treatment of moderate to severe COVID-19 during June through December that included remdesivir and dexamethasone was associated with reduced 30-day mortality and need of MV compared to treatment in February through May.

KW - Adenosine Monophosphate/analogs & derivatives

KW - Alanine/analogs & derivatives

KW - Antiviral Agents/therapeutic use

KW - COVID-19/drug therapy

KW - Cohort Studies

KW - Dexamethasone/therapeutic use

KW - Humans

KW - Retrospective Studies

KW - SARS-CoV-2

U2 - 10.1093/cid/ciab536

DO - 10.1093/cid/ciab536

M3 - Journal article

C2 - 34111274

VL - 73

SP - 2031

EP - 2036

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 11

ER -

ID: 66133261